Morphic Medical launched RESET Therapy, an endoscopic solution designed to deliver immediate weight reduction and metabolic improvement for patients with Type 2 Diabetes and obesity, available in Europe and the UK and limited to Investigational Use in the U.S.

Morphic Medical (formerly GI Dynamics Inc.) is the developer of RESET® (fka EndoBarrier), an endoscopically delivered device therapy that offers a non-surgical, alternative treatment for the treatment of type 2 diabetes and obesity. RESET is approved for sale in the EU and UK and limited to Investigational Use in the U.S. Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts.